Fate Therapeutics announced that preliminary clinical data from the systemic sclerosis arm of its Phase 1 FT819 basket trial will be presented at ISSCR 2026. The first four treated systemic sclerosis patients showed clinical…
Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients.
Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and commercial milestones, creating a total potential transaction value of $1.75 billion. The acquisition gives Ipsen control…
RQ Bio announced the successful completion of an oversubscribed $115 million Series A financing, led by Frazier Life Sciences, to advance its long-acting antibody platform for influenza prevention. The financing will support IND-enabling development…
The FDA approved Trodelvy for first-line metastatic triple-negative breast cancer, significantly expanding Gilead’s commercial opportunity and reinforcing TROP2-directed ADCs as a leading oncology modality.
ADC Therapeutics announced a strategic reorganization that will reduce its workforce by approximately 17%, with resources redirected toward Zynlonta growth opportunities and regulatory priorities. The move follows safety concerns in LOTIS-5 and represents a…
China’s NMPA approved CARsgen’s satri-cel, the first CAR-T therapy approved anywhere in the world for a solid tumor.
Be Biopharma terminated the Phase 1/2 BeCoMe-9 study of BE-101, the first engineered B cell medicine tested clinically in hemophilia B.
InnoCare presented more than 40 orelabrutinib studies at EHA 2026, including the first treatment-naive CLL/SLL clinical data from US and European patients.
Intellia reported additional positive Phase 3 data for lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, reinforcing earlier primary endpoint success and strengthening the regulatory profile of one of the most advanced in vivo CRISPR programs…
